Clinical Efficacy and Immunologic Effects of Omalizumab in Allergic Bronchopulmonary Aspergillosis

Voskamp, Astrid; Gillman, Andrew; Symons, Karen; Sandrini, Alessandra; Rolland, Jennifer M.; O’Hehir, Robyn E; Douglass, Jo A

doi:10.1016/j.jaip.2014.12.008

Cited by 152 publications

(119 citation statements)

References 37 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…Itraconazole (200 mg twice daily) is the recommended choice, but voriconazole and posaconazole have also shown a clinical effect in ABPA [96]. Anti-IgE treatment has been shown to be effective in ABPA patients [153] and may be considered in individual patients.…”

Section: Management Of Severe Asthmamentioning

confidence: 99%

Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults

Porsbjerg

Ulrik

Skjold

et al. 2018

European Clinical Respiratory Journal

View full text Add to dashboard Cite

Although a minority of asthma patients suffer from severe asthma, they represent a major clinical challenge in terms of poor symptom control despite high-dose treatment, risk of exacerbations, and side effects. Novel biological treatments may benefit patients with severe asthma, but are expensive, and are only effective in appropriately targeted patients. In some patients, symptoms are driven by other factors than asthma, and all patients with suspected severe asthma (‘difficult asthma’) should undergo systematic assessment, in order to differentiate between true severe asthma, and ‘difficult-to-treat’ patients, in whom poor control is related to factors such as poor adherence or co-morbidities. The Nordic Consensus Statement on severe asthma was developed by the Nordic Severe Asthma Network, consisting of members from Norway, Sweden, Finland, Denmark, Iceland and Estonia, including representatives from the respective national respiratory scientific societies with the aim to provide an overview and recommendations regarding the diagnosis, systematic assessment and management of severe asthma. Furthermore, the Consensus Statement proposes recommendations for the organization of severe asthma management in primary, secondary, and tertiary care.

show abstract

Section: Management Of Severe Asthmamentioning

confidence: 99%

Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults

Porsbjerg

Ulrik

Skjold

et al. 2018

European Clinical Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…ABPA involving both infectious and allergic processes [101]. A role for anti-IgE therapy has recently been suggested for ABPA [103,104], including in cystic fibrosis [105].…”

Section: Relation Between Ige Responses and Nonspecific Bronchial Hypmentioning

confidence: 99%

Asthma phenotypes and IgE responses

et al. 2015

View full text Add to dashboard Cite

The discovery of IgE represented a major breakthrough in allergy and asthma research, whereas the clinical interest given to IgE in asthma has been blurred until the arrival of anti-IgE biotherapy. Novel facets of the complex link between IgE and asthma have been highlighted by the effect of this treatment and by basic research. In parallel, asthma phenotyping recently evolved to the concept of endotypes, relying on identified/suspected pathobiological mechanisms to phenotype patients, but has not yet clearly positioned IgE among biomarkers of asthma.In this review, we first summarise recent knowledge about the regulation of IgE production and its main receptor, FcεRI. In addition to allergens acting as classical IgE inducers, viral infections as well as air pollution may trigger the IgE pathway, notably resetting the threshold of IgE sensitivity by regulating FcεRI expression. We then analyse the place of IgE in different asthma endo/phenotypes and discuss the potential interest of IgE among biomarkers in asthma. @ERSpublications We summarise regulation of IgE production, and discuss IgE in different asthma endo/ phenotypes and among biomarkers

show abstract

“…Actually, real-world omalizumab dosing in ABPA can be addressed by using a dose calculation resulting in a near-conventional treatment regime [31]. Accordingly, a randomised, double-blind, placebo-controlled omalizumab trial in adult asthmatics with ABPA using a cross-over design and dose regime of 750 mg monthly was recently published, validating the uncontrolled literature: omalizumab works [35]. Validation of similar efficacy in a cystic fibrosis ABPA controlled trial is warranted.…”

mentioning

confidence: 90%

Treating allergic bronchopulmonary aspergillosis: the way forward

Moss

2016

Eur Respir J

View full text Add to dashboard Cite

Clinical Efficacy and Immunologic Effects of Omalizumab in Allergic Bronchopulmonary Aspergillosis

Cited by 152 publications

References 37 publications

Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults

Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults

Asthma phenotypes and IgE responses

Treating allergic bronchopulmonary aspergillosis: the way forward

Contact Info

Product

Resources

About